Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial

IMPORTANCE: Indoleamine 2,3-dioxygenase 1 (IDO1) causes tumor immune suppression. The IDO1 pathway inhibitor indoximod combined with a taxane in patients with ERBB2-negative metastatic breast cancer was tested in a prospective clinical trial. OBJECTIVE: To assess clinical outcomes in patients with E...

詳細記述

保存先:
書誌詳細
出版年:JAMA Oncol
主要な著者: Mariotti, Veronica, Han, Hyo, Ismail-Khan, Roohi, Tang, Shou-Ching, Dillon, Patrick, Montero, Alberto J., Poklepovic, Andrew, Melin, Susan, Ibrahim, Nuhad K., Kennedy, Eugene, Vahanian, Nicholas, Link, Charles, Tennant, Lucy, Schuster, Shelly, Smith, Chris, Danciu, Oana, Gilman, Paul, Soliman, Hatem
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2020
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7645745/
https://ncbi.nlm.nih.gov/pubmed/33151286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.5572
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料